To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Study Supports Role Of Anticort In Treating Alzheimer's, HIV URL: http://www.pslgroup.com/dg/6D5E2.htm Doctor's Guide April 17, 1998
LAS VEGAS, NV -- April 17, 1998 -- New study results show that Steroidogenesis Inhibitors International's Anticort(TM), the world's first drug designed expressly to reduce elevated levels of the stress hormone cortisol, may be effective in treating Alzheimer's, other age-related diseases and AIDS. Cortisol's role as a cause of disease is most recently confirmed in a study to be published in the May issue of the journal Nature Neuroscience. Authored by Dr. Sonia Lupien of McGill University, the study reports that high levels of cortisol play a key role in Alzheimer's, memory loss, shrinkage of the brain and aging. Dr. Lupien also states that such illnesses might be prevented with medications to reduce elevated cortisol levels. Anticort is an anti-cortisol (steroidogenesis inhibitor) drug that prevents and treats the deadly immunosuppressive effects of elevated cortisol. When Dr. Sapse first began to evaluate Anticort's therapeutic potential, AIDS and Alzheimer's presented themselves as the two diseases most likely to be responsive. Due to the rapid spread of AIDS and the immense suffering associated with the fatal disease, Dr. Sapse decided to initially focus on HIV-positive patients. A preliminary study of 60 HIV-positive patients in Brazil found Anticort to be effective in increasing CD4 (immune cell) counts and drastically reducing mortality. After submitting a comprehensive clinical program, STGI has received FDA approval to begin clinically testing Anticort on HIV-positive patients under a Phase IB/IIA setting. Anticort's effectiveness in the treatment of Alzheimer's is equally promising. The drug reduces both cortisol and cholinesterase -- an enzyme responsible for destroying the key neurotransmitter acetylcholine. The McGill study serves as a strong catalyst to begin testing Anticort for the treatment of Alzheimer's patients. The company is planning to begin such tests later this year. More information on: Anticort and Steroidogenesis Inhibitors International. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.